Resistance to Antibacterials in Human Pathogens

Dear Colleagues,

The progressive increase in resistances to antibiotics in bacterial human pathogens is a worldwide public health concern. The World Health Organization has defined the priority pathogens for which an increase in the prevalence of antibiotic resistances might lead to significant reduction in antibiotic therapy alternatives. Common human pathogens that frequently develop multidrug resistance (MDR), and occasionally extensively drug resistance (XDR), include methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, the enterobacteria producing extended spectrum beta-lactamases (ESBL) or carbapenemases (CARB), Pseudomonas aeruginosa (ESBL or CARB), and Acinetobacter baumanii (ESBL or CARB). Mycobacterium tuberculosis (MDR or XDR phenotypes) remains a significant human pathogen worldwide. Many other bacterial species have developed antibiotic resistances. The aim of this topic is to provide an up-to-date overview of the current situation of antimicrobial resistances in human bacterial pathogens. Publications may deal with epidemiological data, medical data, economic data, antibiotic resistance phenotypes and genotypes, new methodologies for assessing antibiotic resistances (including whole genome sequencing), and genetic mechanisms of the emergence and spread of antibiotic resistances. This topic is focused on human bacterial pathogens and resistance to antibiotics but is not restricted to specific bacterial species.

Prof. Dr. Max Maurin
Dr. Daniela Eletto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.